{"title_page": "CYP2U1", "text_new": "{{Infobox_gene}}\n\n'''CYP2U1''' ('''cy'''tochrome '''P'''450, family '''2''', subfamily '''U''', polypeptide '''1''') is a [[protein]] that in humans is encoded by the ''CYP2U1'' [[gene]]<ref name=\"pmid14660610\">{{cite journal | vauthors = Chuang SS, Helvig C, Taimi M, Ramshaw HA, Collop AH, Amad M, White JA, Petkovich M, Jones G, Korczak B | title = CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids | journal = The Journal of Biological Chemistry | volume = 279 | issue = 8 | pages = 6305\u201314 | date = Feb 2004 | pmid = 14660610 | doi = 10.1074/jbc.M311830200 }}</ref>\n\n== Function ==\n\nThis gene encodes a member of the [[cytochrome P450]] superfamily of enzymes. The cytochrome P450 proteins are [[monooxygenase]]s which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and the hydroxylation of fatty acids and fatty acid metabolites.<ref name=\"entrez\">{{cite web | title = Entrez Gene: CYP2U1 | url =https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=113612 | accessdate = }}</ref> CYP2U1 metabolized [[arachidonic acid]], [[docosahexaenoic acid]] (DHA), and other long chain [[fatty acid]]s which suggests that CYP2U1 may play a role in brain and immune functions.<ref name=\"pmid14660610\"/> CYP2U1 also metabolizes [[propanone]], [[acetone]], and 2-oxypropane.\n\n== Tissue distribution ==\n\nThe CYP2U1 gene is a highly conserved gene that is mainly expressed in brain and thymus, but also at lower levels in kidney, lung, and heart.<ref>{{cite journal | vauthors = Devos A, Lino Cardenas CL, Glowacki F, Engels A, Lo-Guidice JM, Chevalier D, Allorge D, Broly F, Cauffiez C | title = Genetic polymorphism of CYP2U1, a cytochrome P450 involved in fatty acids hydroxylation | journal = Prostaglandins, Leukotrienes, and Essential Fatty Acids | volume = 83 | issue = 2 | pages = 105\u201310 | date = Aug 2010 | pmid = 20630735 | doi = 10.1016/j.plefa.2010.06.005 }}</ref>\n\n== Reactions ==\n\nCYP2U1 hydroxylates [[arachidonic acid]], [[docosahexaenoic acid]] (DHA), and other long chain [[fatty acid]]s at their terminal (i.e., \u03c9) carbon to form 20-hydroxy-arachidonic acid (i.e. [[20-Hydroxyeicosatetraenoic acid]] or 20-HETE), 22-hydroxy-docosahexaneoic acid, and other \u03c9-hydroxy long chain fatty acids, respectively, plus lesser amounts of these fatty acids \u03c9-1 hydroxy metabolites, i.e. 19-HETE, 21-hydroxy-docosahexaenoic acid, and other \u03c9-1 hydroxy long chain fatty acids, respectively.<ref name=\"pmid14660610\"/>  One of these metabolites, 20-HETE, is a regulator of blood pressure and blood flow to organs in animal models and, based on genetic studies, possibly in humans (see [[20-Hydroxyeicosatetraenoic acid]]).\n\n== Clinical significance ==\n\nA mutation (c.947A>T) in CYP2U1 has been associated in a very small number of patients with [[Hereditary spastic paraplegia]] in that it segregates with the disease at the homozygous state in two afflicted families.  This mutation affects an amino acid (p.Asp316Val) that is highly conserved among CYP2U1 [[orthologs]] as well as other cytochrome P450 proteins; this p.Asp314Val mutation is located in the enzyme's functional domain, is predicted to be damaging to the enzyme's activity, and is associated with [[mitochondria]] dysfunction.<ref name = \"Tesson_2012\">{{cite journal | vauthors = Tesson C, Nawara M, Salih MA, Rossignol R, Zaki MS, Al Balwi M, Schule R, Mignot C, Obre E, Bouhouche A, Santorelli FM, Durand CM, Oteyza AC, El-Hachimi KH, Al Drees A, Bouslam N, Lamari F, Elmalik SA, Kabiraj MM, Seidahmed MZ, Esteves T, Gaussen M, Monin ML, Gyapay G, Lechner D, Gonzalez M, Depienne C, Mochel F, Lavie J, Schols L, Lacombe D, Yahyaoui M, Al Abdulkareem I, Zuchner S, Yamashita A, Benomar A, Goizet C, Durr A, Gleeson JG, Darios F, Brice A, Stevanin G | display-authors = 6 | title = Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia | journal = American Journal of Human Genetics | volume = 91 | issue = 6 | pages = 1051\u201364 | date = Dec 2012 | pmid = 23176821 | doi = 10.1016/j.ajhg.2012.11.001 | pmc=3516610}}</ref><ref>{{cite journal | vauthors = Wortmann SB, Espeel M, Almeida L, Reimer A, Bosboom D, Roels F, de Brouwer AP, Wevers RA | title = Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids | journal = Journal of Inherited Metabolic Disease | volume = 38 | issue = 1 | pages = 99\u2013110 | date = Jan 2015 | pmid = 25178427 | doi = 10.1007/s10545-014-9759-7 }}</ref>  A second homozygous enzyme-disabling mutation has been identified in CYP2U1, c.1A>C/p.Met1?, that is associated with <1% of hereditary spastic paraplegia sufferers.<ref name=\"pmid24337409\">{{cite journal | vauthors = Citterio A, Arnoldi A, Panzeri E, D'Angelo MG, Filosto M, Dilena R, Arrigoni F, Castelli M, Maghini C, Germiniasi C, Menni F, Martinuzzi A, Bresolin N, Bassi MT | title = Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis | journal = J. Neurol. | volume = 261 | issue = 2 | pages = 373\u201381 | year = 2014 | pmid = 24337409 | doi = 10.1007/s00415-013-7206-6 | url = https://air.unimi.it/bitstream/2434/421160/2/Citterio%20J%20Neurol%202014.pdf }}</ref>  The reduction in 20-HETE production by these mutations, and thereby in 20-HETE's activation of the [[TRPV1]] neural receptor, it is hypothesized, may contribute to the development of this disease (see [[20-Hydroxyeicosatetraenoic acid]] for details).<ref name = \"Tesson_2012\"/>\n\nCYPU21 along with members of the CYP4A and CYP4F sub-families also \u03c9-hydroxylate and thereby reduce the activity of various fatty acid metabolites of arachidonic acid including [[LTB4]], [[5-HETE]], [[5-oxo-eicosatetraenoic acid]], [[12-HETE]], and several [[prostaglandins]] that are involved in regulating various inflammatory, vascular, and other responses in animals and humans.<ref>{{cite journal | doi = 10.1016/j.bcp.2008.03.004 | volume=75 | title=Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases | year=2008 | journal=Biochemical Pharmacology | pages=2263\u20132275 | vauthors=Hardwick JP}}</ref> This hydroxylation-induced inactivation may underlie the proposed roles of the cytochromes in dampening inflammatory responses and the reported associations of certain CYP4F2 and CYP4F3 [[single nucleotide variant]]s with human [[Krohn's disease]] and [[Coeliac disease]], respectively.<ref>Eur J Hum Genet. 2006 Nov;14(11):1215-22</ref><ref>{{cite journal | doi = 10.1515/dmdi-2011-0037 | volume=27 | title=Human cytochrome P450 4F3: structure, functions, and prospects | year=2012 | journal=Drug Metabolism and Drug Interactions | vauthors=Corcos L}}</ref><ref>{{cite journal | doi = 10.1053/j.gastro.2013.12.034 | volume=146 | title=Interactions Between the Dietary Polyunsaturated Fatty Acid Ratio and Genetic Factors Determine Susceptibility to Pediatric Crohn's Disease | year=2014 | journal=Gastroenterology | pages=929\u2013931.e3 | vauthors=Costea I}}</ref>\n\n== References ==\n{{Reflist|33em}}\n\n==External links==\n* {{UCSC gene info|CYP2U1}}\n\n== Further reading ==\n{{refbegin|33em}}\n* {{cite journal | vauthors = Nelson DR | title = 'Frankenstein genes', or the Mad Magazine version of the human pseudogenome | journal = Human Genomics | volume = 1 | issue = 4 | pages = 310\u20136 | date = May 2004 | pmid = 15588491 | pmc = 3525266 | doi =  }}\n* {{cite journal | vauthors = Wistow G, Bernstein SL, Ray S, Wyatt MK, Behal A, Touchman JW, Bouffard G, Smith D, Peterson K | title = Expressed sequence tag analysis of adult human iris for the NEIBank Project: steroid-response factors and similarities with retinal pigment epithelium | journal = Molecular Vision | volume = 8 | issue =  | pages = 185\u201395 | date = Jun 2002 | pmid = 12107412 | doi =  }}\n* {{cite journal | vauthors = Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW | title = Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants | journal = Pharmacogenetics | volume = 14 | issue = 1 | pages = 1\u201318 | date = Jan 2004 | pmid = 15128046 | doi = 10.1097/00008571-200401000-00001 }}\n* {{cite journal | vauthors = Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M | title = Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1 | journal = Biochemical and Biophysical Research Communications | volume = 315 | issue = 3 | pages = 679\u201385 | date = Mar 2004 | pmid = 14975754 | doi = 10.1016/j.bbrc.2004.01.110 }}\n{{refend}}\n\n{{NLM content}}\n{{Cytochrome P450}}\n", "text_old": "{{Infobox_gene}}\n\n'''CYP2U1''' ('''cy'''tochrome '''P'''450, family '''2''', subfamily '''U''', polypeptide '''1''') is a [[protein]] that in humans is encoded by the ''CYP2U1'' [[gene]]<ref name=\"pmid14660610\">{{cite journal | vauthors = Chuang SS, Helvig C, Taimi M, Ramshaw HA, Collop AH, Amad M, White JA, Petkovich M, Jones G, Korczak B | title = CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids | journal = The Journal of Biological Chemistry | volume = 279 | issue = 8 | pages = 6305\u201314 | date = Feb 2004 | pmid = 14660610 | doi = 10.1074/jbc.M311830200 }}</ref>\n\n== Function ==\n\nThis gene encodes a member of the [[cytochrome P450]] superfamily of enzymes. The cytochrome P450 proteins are [[monooxygenase]]s which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and the hydroxylation of fatty acids and fatty acid metabolites.<ref name=\"entrez\">{{cite web | title = Entrez Gene: CYP2U1 | url =https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=113612 | accessdate = }}</ref> CYP2U1 metabolized [[arachidonic acid]], [[docosahexaenoic acid]] (DHA), and other long chain [[fatty acid]]s which suggests that CYP2U1 may play a role in brain and immune functions.<ref name=\"pmid14660610\"/> CYP2U1 also metabolizes [[propanone]], [[acetone]], and 2-oxypropane.\n\n== Tissue distribution ==\n\nThe CYP2U1 gene is a highly conserved gene that is mainly expressed in brain and thymus, but also at lower levels in kidney, lung, and heart.<ref>{{cite journal | vauthors = Devos A, Lino Cardenas CL, Glowacki F, Engels A, Lo-Guidice JM, Chevalier D, Allorge D, Broly F, Cauffiez C | title = Genetic polymorphism of CYP2U1, a cytochrome P450 involved in fatty acids hydroxylation | journal = Prostaglandins, Leukotrienes, and Essential Fatty Acids | volume = 83 | issue = 2 | pages = 105\u201310 | date = Aug 2010 | pmid = 20630735 | doi = 10.1016/j.plefa.2010.06.005 }}</ref>\n\n== Reactions ==\n\nCYP2U1 hydroxylates [[arachidonic acid]], [[docosahexaenoic acid]] (DHA), and other long chain [[fatty acid]]s at their terminal (i.e., \u03c9) carbon to form 20-hydroxy-arachidonic acid (i.e. [[20-Hydroxyeicosatetraenoic acid]] or 20-HETE), 22-hydroxy-docosahexaneoic acid, and other \u03c9-hydroxy long chain fatty acids, respectively, plus lesser amounts of these fatty acids \u03c9-1 hydroxy metabolites, i.e. 19-HETE, 21-hydroxy-docosahexaenoic acid, and other \u03c9-1 hydroxy long chain fatty acids, respectively.<ref name=\"pmid14660610\"/>  One of these metabolites, 20-HETE, is a regulator of blood pressure and blood flow to organs in animal models and, based on genetic studies, possibly in humans (see [[20-Hydroxyeicosatetraenoic acid]]).\n\n== Clinical significance ==\n\nA mutation (c.947A>T) in CYP2U1 has been associated in a very small number of patients with [[Hereditary spastic paraplegia]] in that it segregates with the disease at the homozygous state in two afflicted families.  This mutation affects an amino acid (p.Asp316Val) that is highly conserved among CYP2U1 [[orthologs]] as well as other cytochrome P450 proteins; this p.Asp314Val mutation is located in the enzyme's functional domain, is predicted to be damaging to the enzyme's activity, and is associated with [[mitochondria]] dysfunction.<ref name = \"Tesson_2012\">{{cite journal | vauthors = Tesson C, Nawara M, Salih MA, Rossignol R, Zaki MS, Al Balwi M, Schule R, Mignot C, Obre E, Bouhouche A, Santorelli FM, Durand CM, Oteyza AC, El-Hachimi KH, Al Drees A, Bouslam N, Lamari F, Elmalik SA, Kabiraj MM, Seidahmed MZ, Esteves T, Gaussen M, Monin ML, Gyapay G, Lechner D, Gonzalez M, Depienne C, Mochel F, Lavie J, Schols L, Lacombe D, Yahyaoui M, Al Abdulkareem I, Zuchner S, Yamashita A, Benomar A, Goizet C, Durr A, Gleeson JG, Darios F, Brice A, Stevanin G | display-authors = 6 | title = Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia | journal = American Journal of Human Genetics | volume = 91 | issue = 6 | pages = 1051\u201364 | date = Dec 2012 | pmid = 23176821 | doi = 10.1016/j.ajhg.2012.11.001 | pmc=3516610}}</ref><ref>{{cite journal | vauthors = Wortmann SB, Espeel M, Almeida L, Reimer A, Bosboom D, Roels F, de Brouwer AP, Wevers RA | title = Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids | journal = Journal of Inherited Metabolic Disease | volume = 38 | issue = 1 | pages = 99\u2013110 | date = Jan 2015 | pmid = 25178427 | doi = 10.1007/s10545-014-9759-7 }}</ref>  A second homozygous enzyme-disabling mutation has been identified in CYP2U1, c.1A>C/p.Met1?, that is associated with <1% of hereditary spastic paraplegia sufferers.<ref name=\"pmid24337409\">{{cite journal | vauthors = Citterio A, Arnoldi A, Panzeri E, D'Angelo MG, Filosto M, Dilena R, Arrigoni F, Castelli M, Maghini C, Germiniasi C, Menni F, Martinuzzi A, Bresolin N, Bassi MT | title = Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis | journal = J. Neurol. | volume = 261 | issue = 2 | pages = 373\u201381 | year = 2014 | pmid = 24337409 | doi = 10.1007/s00415-013-7206-6 | url = https://air.unimi.it/bitstream/2434/421160/2/Citterio%20J%20Neurol%202014.pdf }}</ref>  The reduction in 20-HETE production by these mutations, and thereby in 20-HETE's activation of the [[TRPV1]] neural receptor, it is hypothesized, may contribute to the development of this disease (see [[20-Hydroxyeicosatetraenoic acid]] for details).<ref name = \"Tesson_2012\"/>\n\nCYPU21 along with members of the CYP4A and CYP4F sub-families also \u03c9-hydroxylate and thereby reduce the activity of various fatty acid metabolites of arachidonic acid including [[LTB4]], [[5-HETE]], [[5-oxo-eicosatetraenoic acid]], [[12-HETE]], and several [[prostaglandins]] that are involved in regulating various inflammatory, vascular, and other responses in animals and humans.<ref>Arch Biochem Biophys. 1998 Jul 15;355(2):201</ref><ref>Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004</ref> This hydroxylation-induced inactivation may underlie the proposed roles of the cytochromes in dampening inflammatory responses and the reported associations of certain CYP4F2 and CYP4F3 [[single nucleotide variant]]s with human [[Krohn's disease]] and [[Coeliac disease]], respectively.<ref>Eur J Hum Genet. 2006 Nov;14(11):1215-22</ref><ref>Drug Metabol Drug Interact. 2012 Apr 19;27(2):63-71. doi: 10.1515/dmdi-2011-0037</ref><ref>Gastroenterology. 2014 Apr;146(4):929-31. doi: 10.1053/j.gastro.2013.12.034</ref>\n\n== References ==\n{{Reflist|33em}}\n\n==External links==\n* {{UCSC gene info|CYP2U1}}\n\n== Further reading ==\n{{refbegin|33em}}\n* {{cite journal | vauthors = Nelson DR | title = 'Frankenstein genes', or the Mad Magazine version of the human pseudogenome | journal = Human Genomics | volume = 1 | issue = 4 | pages = 310\u20136 | date = May 2004 | pmid = 15588491 | pmc = 3525266 | doi =  }}\n* {{cite journal | vauthors = Wistow G, Bernstein SL, Ray S, Wyatt MK, Behal A, Touchman JW, Bouffard G, Smith D, Peterson K | title = Expressed sequence tag analysis of adult human iris for the NEIBank Project: steroid-response factors and similarities with retinal pigment epithelium | journal = Molecular Vision | volume = 8 | issue =  | pages = 185\u201395 | date = Jun 2002 | pmid = 12107412 | doi =  }}\n* {{cite journal | vauthors = Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW | title = Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants | journal = Pharmacogenetics | volume = 14 | issue = 1 | pages = 1\u201318 | date = Jan 2004 | pmid = 15128046 | doi = 10.1097/00008571-200401000-00001 }}\n* {{cite journal | vauthors = Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M | title = Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1 | journal = Biochemical and Biophysical Research Communications | volume = 315 | issue = 3 | pages = 679\u201385 | date = Mar 2004 | pmid = 14975754 | doi = 10.1016/j.bbrc.2004.01.110 }}\n{{refend}}\n\n{{NLM content}}\n{{Cytochrome P450}}\n", "name_user": "Rjwilmsi", "label": "safe", "comment": "\u2192\u200eClinical significance:Journal cites:,", "url_page": "//en.wikipedia.org/wiki/CYP2U1"}
